Sooma Pain Therapy

Relief Without Opioids

  • A non-invasive brain stimulation therapy

  • Pain relief in just two weeks1

  • No serious or systemic side effects2

Read the latest meta-analysis

Zortea, et al. (2019) N = 1007

We feel that everyone deserves high quality care. Sooma Pain Therapy provides an effective tool for management of pain that is also accessible by primary care and family doctors. Offer your patients pain relief without fear of addiction. Treat patients, who are unable to visit the clinic, efficiently without compromising safety.

Effective pain relief with Sooma Pain Therapy

Sooma Pain Therapy offers effective pain relief and helps reduce analgesic use. This is done by modulating the sensory and affective processing of pain using non-invasive brain stimulation1. A portable medical device is used for the therapy. A treatment session lasts for 20-minutes and it is repeated once a day for a minimum of two weeks to achieve a therapeutic response. The therapy is prescribed by a physician but the treatment sessions can be administered at home. The treatment is painless and the patient may continue with regular activities after the session.

Pain relief in just 2 weeks

A treatment session lasts for 20-minutes and it is repeated five times per week for minimum of 2 weeks.

Repeated sessions are required to achieve behavioural effects and pain relief, but the effects of even a single session can be measured via MEP3, MEG4, TMS-EEG5, fMRI6 and epidural electrode7. Adherence to all treatment sessions is important for optimal pain relief.

Modulation of neuronal activity to relieve chronic pain

The placement of electrodes is critical to the success of the therapy. As such, we use an intuitive head cap that enables a reproducible electrode placement to targeted locations on the scalp. The excitatory stimulation is delivered to the motor area, while the contralateral supraorbital area undergoes inhibitory stimulation. The side of excitatory stimulation is governed by (a) handedness and (b) pain origin so that the anode is positioned over the dominant hemisphere or contralaterally to the side of local pain as demonstrated in Figure 1.

Electrode placement for Sooma Pain Therapy

Figure 1. Electrodes placement in Sooma Pain Therapy is dependant on (a) handedness and (b) pain origin.

Sooma Pain Therapy is intended for patients suffering from chronic pain such as Fibromyalgia and chronic neuropathic pain. The patient may undergo simultaneous treatments, to which Sooma Pain Therapy is added on.

A wide variety of healthcare service providers may benefit from Sooma Pain Therapy. The therapy is well-suited as a first line treatment delivered by a primary care physician or a family doctor. Moreover, Sooma Pain Therapy can add significant value to the toolbox of a university hospital.

Applying the therapy is easy

Sooma Depression Therapy head cap and stimulation device

Figure 2. Sooma Pain Therapy utilises a small portable medical device called Sooma tDCS. The system consists of a stimulator unit, two electrodes with colour-coded cables, a head cap for electrode positioning and a stimulation pad that forms the contact surface between a patient and the electrode.

The stimulation is delivered using a Class IIa-medical device: Sooma tDCS™. The stimulator unit is indicated for the treatment of depression and chronic pain. As such, its users are covered by a liability insurance when applying stimulation with Sooma tDCS to these indications. Sooma tDCS features a single control button that is used to start and pause the stimulation. Everything else, including ending a session, is automated for your convenience and to prevent accidental modification of stimulation output. The stimulator unit is portable enabling normal movement during stimulation. Consequently, the stimulation can be done while reading a book, walking a dog, doing office work etc.

Sooma Software suite: mobile application for mood recoding

Figure 3. Sooma Software Suite may be used to monitor a patient during Sooma Depression Therapy. The patient records their mood and well-being information daily using a mobile application.

A physician is able to follow the progress of home-based patients during Sooma Pain Therapy via Sooma Software Suite. An application is installed on the patient’s mobile phone, which is used to record data about wellbeing and daily levels of pain. The data is synchronised to a cloud which the physician is able to access via internet browser. Using the data, the physician is able to monitor the treatment progress and make instant changes to treatment schedule. Access to Sooma Software Suite is included in Sooma Pain Therapy.

Sooma Pain Therapy is well tolerated and not associated with serious adverse events. 84% of patients complete the treatment course successfully even if they are required to visit a clinic for every treatment session. A safety review, based on over 40 000 stimulation sessions, concluded that the technique is safe even when used in adolescent or elderly population2. Typical side effects include itching under the electrodes during stimulation and a transient headache after the stimulation. FDA views the stimulation to be without a reasonable expectation of any serious adverse event2, a stance that has been adopted also by NICE8.

No dangerous interactions with pharmaceuticals have been reported2. Consumption of nicotine and alcohol should be avoided during the therapy to ensure optimal efficiency. Contraindications for the therapy are metal implants within the skull, a pacemaker, head area surgery within the last 6 months, and acute eczema in the stimulation area.

Available for you

Sooma Pain Therapy is available worldwide through a wide network of local partners. It has CE and Health Canada approvals among others. Contact us to know more.

References

  1. Zortea, et al. Transcranial Direct Current Stimulation to Improve the Dysfunction of Descending Pain Modulatory System Related to Opioids in Chronic Non-cancer Pain: An Integrative Review of Neurobiology and Meta-Analysis. Front Neurosci. 2019; 13: 1218.
  2. Bikson M, et al. Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimul. 2016 Sep-Oct;9(5):641-61.
  3. Nitsche MA ja Paulus W. Excitability changes induced in the human motor cortex by weak transcranial direct current stimulation. J Physiol. 2000 Sep 15;527 Pt 3:633-9.
  4. Pellegrino et al. Bilateral Transcranial Direct Current Stimulation Reshapes Resting-State Brain Networks: A Magnetoencephalography Assessment. Neural Plasticity, vol. 2018, Article ID 2782804, 10 pages, 2018.
  5. Romero Lauro et al. TDCS increases cortical excitability: direct evidence from TMS-EEG. Cortex. 2014 Sep;58:99-111.
  6. Keeser D et al. Prefrontal Transcranial Direct Current Stimulation Changes Connectivity of Resting-State Networks during fMRI. Journal of Neuroscience 26 October 2011, 31 (43) 15284-15293
  7. Di Lazzaro V et al. Transcranial Direct Current Stimulation Effects on the Excitability of Corticospinal Axons of the Human Cerebral Cortex. Brain Stimulation 6 (2013) 641-643
  8. National Institute of Care Excellence – Interventional guidance IPG530 (2015) Available online: https://www.nice.org.uk/guidance/ipg530
Sooma Depression Therapy accessories